771-81-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinecarboxylic acid, 4-amino-2-(methylthio)is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential anticancer and antitumor properties. It aids in the development of drugs targeting cancer cells and tumor growth, offering a promising avenue for cancer treatment and management.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Pyrimidinecarboxylic acid, 4-amino-2-(methylthio)is utilized as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its antimicrobial and antiviral activities contribute to the development of effective solutions for crop protection and disease management in agriculture.
Used in Organic Electronics:
5-Pyrimidinecarboxylic acid, 4-amino-2-(methylthio)has potential applications in the field of organic electronics, where its unique chemical structure and properties can be harnessed for the development of novel electronic materials and devices, such as organic light-emitting diodes (OLEDs) and organic solar cells.
Used in Antimicrobial Applications:
Due to its antimicrobial properties, 5-Pyrimidinecarboxylic acid, 4-amino-2-(methylthio)can be employed as an antimicrobial agent in various industries, including healthcare, food preservation, and water treatment. It can help combat bacterial infections and contamination, ensuring safety and quality in these sectors.
Used in Antiviral Applications:
The antiviral activity of 5-Pyrimidinecarboxylic acid, 4-amino-2-(methylthio)makes it a potential candidate for the development of antiviral drugs and therapies. It can be used to treat and prevent viral infections in both humans and animals, contributing to the control and management of viral diseases.

Upstream product

• 776-53-4 ethyl 4-amino-2-methylmercaptopyrimidine-5-carboxylate 
• 774-07-2 ethyl 4-amino-2-thioxo-1H-pyrimidine-5-carboxylate 
• 77-78-1 dimethyl sulfate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 

Downstream Products

• 588-36-3 (4-amino-2-(methylthio)pyrimidin-5-yl)methanol 
• 89533-28-8 4-amino-2-methylthiopyrimidine-5-carboxamide 
• 832114-37-1 N-(4-methoxybenzyl)-4-amino-2-methylmercaptopyrimidine-5-carboxamide 

Relevant academic research and scientific papers

A synthetic DNA - PK inhibitors STL127705 method (by machine translation)

The invention discloses a method for synthesizing DNA - PK inhibitors STL127705 method. This invention adopts the retrosynthetic analysis, in order to 2 - sulfide - 4 - chloro pyrimidine - 5 - carboxylic acid ethyl ester as the starting material, successi

Pyridopyrimidinone derivatives as potent and selective c-jun N-terminal kinase (JNK) inhibitors

A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure-activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 ?. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.

NOVEL COMPOUNDS AS JNK KINASE INHIBITORS

The present invention is directed to modulators, such as inhibitors, of JNK isoform 2 (JNK2) or isoform 3 (JNK3) comprising compounds of formula (I) or formula (II) as described herein. Compounds of the invention can be used for treatment of a medical dis

P-38 kinase inhibitors

Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.